{"id":59507,"date":"2026-05-04T00:43:38","date_gmt":"2026-05-04T00:43:38","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/59507\/"},"modified":"2026-05-04T00:43:38","modified_gmt":"2026-05-04T00:43:38","slug":"novartis-profit-sales-decline-as-generic-competition-bites","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/59507\/","title":{"rendered":"Novartis Profit, Sales Decline as Generic Competition Bites"},"content":{"rendered":"<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\"><a href=\"https:\/\/www.bloomberg.com\/quote\/NOVN:SW\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Novartis AG<\/a>\u2019s profit fell more than estimated and sales unexpectedly declined in the first quarter as some of the drugmaker\u2019s best-selling medicines were hit hard by generic competition. <\/p>\n<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">Core operating profit dropped 12% to $4.9 billion, Novartis <a href=\"https:\/\/www.bloomberg.com\/news\/terminal\/TE6TW1TVI5MT\" class=\"media-ui-Link_link-tVkXhPLPofs- whitespace-normal\" target=\"_blank\" rel=\"noopener nofollow\" data-component=\"link\">said TuesdayBloomberg Terminal<\/a>. Analysts surveyed by Bloomberg estimated earnings of $5.18 billion. Revenue showed the first decrease in almost two years, according to Bloomberg data. <\/p>\n","protected":false},"excerpt":{"rendered":"Novartis AG\u2019s profit fell more than estimated and sales unexpectedly declined in the first quarter as some of&hellip;\n","protected":false},"author":2,"featured_media":59508,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[2112,7437,3585,4397,230,10622,2918,19921,206,13223,17,9827],"class_list":{"0":"post-59507","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-cancer","9":"tag-chief-executive-officer","10":"tag-chief-financial-officer","11":"tag-drugs","12":"tag-earnings","13":"tag-industries","14":"tag-morgan-stanley","15":"tag-mukul-mehta","16":"tag-novartis","17":"tag-novartis-ag-reg","18":"tag-switzerland","19":"tag-vas-narasimhan"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116513538353603508","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/59507","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=59507"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/59507\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/59508"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=59507"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=59507"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=59507"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}